DK2253644T3 - Sammensætninger og fremgangsmåder til fremstilling af en sammensætning - Google Patents

Sammensætninger og fremgangsmåder til fremstilling af en sammensætning

Info

Publication number
DK2253644T3
DK2253644T3 DK10153282.8T DK10153282T DK2253644T3 DK 2253644 T3 DK2253644 T3 DK 2253644T3 DK 10153282 T DK10153282 T DK 10153282T DK 2253644 T3 DK2253644 T3 DK 2253644T3
Authority
DK
Denmark
Prior art keywords
compositions
preparing
composition
methods
Prior art date
Application number
DK10153282.8T
Other languages
English (en)
Inventor
Robert Donaldson
Ajoy Velayudhan
Jeffrey Schrimsher
Kirk Leister
Eugene J Schaefer
Ronald Bates
Elizabeth A Bramhall
David M Didio
Alan R Flesher
Helen G Haggerty
David H Kirkley
John M Tabor
Lee K Tay
Pallaiah Thammana
David E Smolin
Reb J Russell
Boom Thomas Vanden
Joyce Whitehead
Dean Brownell
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2253644(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK2253644T3 publication Critical patent/DK2253644T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
DK10153282.8T 2005-12-20 2006-12-19 Sammensætninger og fremgangsmåder til fremstilling af en sammensætning DK2253644T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75215005P 2005-12-20 2005-12-20
US75226705P 2005-12-20 2005-12-20
US84954306P 2006-10-05 2006-10-05
EP06848052.4A EP1969007B1 (en) 2005-12-20 2006-12-19 Compositions and methods for producing a composition

Publications (1)

Publication Number Publication Date
DK2253644T3 true DK2253644T3 (da) 2014-01-13

Family

ID=38218674

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10153282.8T DK2253644T3 (da) 2005-12-20 2006-12-19 Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
DK06848052.4T DK1969007T3 (da) 2005-12-20 2006-12-19 Sammensætninger og fremgangsmåder til fremstilling af en sammensætning

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06848052.4T DK1969007T3 (da) 2005-12-20 2006-12-19 Sammensætninger og fremgangsmåder til fremstilling af en sammensætning

Country Status (25)

Country Link
US (4) US10508144B2 (da)
EP (2) EP1969007B1 (da)
JP (2) JP5096369B2 (da)
KR (2) KR101391457B1 (da)
CN (1) CN106589132B (da)
AU (2) AU2006330922B2 (da)
BR (2) BRPI0620178B1 (da)
CA (2) CA2634760C (da)
CY (1) CY1114887T1 (da)
DK (2) DK2253644T3 (da)
EA (1) EA017765B1 (da)
ES (2) ES2433092T3 (da)
HK (1) HK1121173A1 (da)
HR (1) HRP20130975T1 (da)
IL (2) IL192098A (da)
MX (1) MX336807B (da)
NO (1) NO20082716L (da)
NZ (1) NZ597215A (da)
PE (1) PE20080556A1 (da)
PL (2) PL1969007T4 (da)
PT (2) PT2253644E (da)
SI (2) SI2253644T1 (da)
TW (2) TWI398520B (da)
WO (1) WO2007076032A2 (da)
ZA (1) ZA200805301B (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
TWI398520B (zh) 2005-12-20 2013-06-11 必治妥美雅史谷比公司 組合物及製造組合物之方法
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
US7884184B2 (en) 2007-01-30 2011-02-08 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
EP3470093B1 (en) 2008-10-06 2020-08-19 3-D Matrix Ltd. Tissue plug
CN101995476B (zh) * 2009-08-10 2013-07-03 中国医学科学院北京协和医院 临床化学检验用液体质控血清
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US20110136682A1 (en) 2009-12-04 2011-06-09 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
KR20120118065A (ko) * 2010-02-12 2012-10-25 디에스엠 아이피 어셋츠 비.브이. 단일 단위체 항체 정제
CN106432474A (zh) 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
US20120121574A1 (en) * 2010-11-15 2012-05-17 Luciano Polonelli Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore
JP5847418B2 (ja) 2011-03-30 2016-01-20 富士フイルム株式会社 細胞接着性タンパク質
MX2013013054A (es) * 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
US20150038362A1 (en) * 2012-02-27 2015-02-05 Biogen Idec Ma Inc. High-Throughput Method For Sialic Acid Quantitation
EP2841952A4 (en) * 2012-04-22 2015-12-02 Perfinity Biosciences Inc AUTOMATED PROTEIN DEDUCTION, RECOVERY AND ANALYSIS
LT2867251T (lt) * 2012-06-29 2019-11-25 Bristol Myers Squibb Co Glikoproteinų agregacijos sumažinimo būdai
EP3466964A1 (en) * 2012-07-06 2019-04-10 3-D Matrix Ltd. Fill-finish process for peptide solutions
WO2014149067A1 (en) * 2013-03-15 2014-09-25 Momenta Pharmaceuticals, Inc. Methods related to ctla4-fc fusion proteins
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6684719B2 (ja) 2014-03-10 2020-04-22 株式会社スリー・ディー・マトリックス ペプチド組成物の滅菌および濾過
CA2939696C (en) 2014-03-10 2023-01-10 3-D Matrix, Ltd. Self-assembling peptide compositions
BR112016023450A2 (pt) 2014-04-25 2017-10-17 Bristol Myers Squibb Co uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce
JP6948942B2 (ja) * 2014-10-15 2021-10-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド タンパク質産物の等電性プロファイルをシフトさせる方法およびその使用
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
LT3283508T (lt) 2015-04-17 2021-07-12 Alpine Immune Sciences, Inc. Imunomoduliuojantys baltymai su sureguliuojamu giminingumu
WO2016201323A1 (en) 2015-06-10 2016-12-15 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
TWI579030B (zh) * 2015-12-15 2017-04-21 Ｃｇ生物技術有限公司 分離細胞之容器、系統及方法
WO2017120092A1 (en) 2016-01-06 2017-07-13 3-D Matrix, Ltd. Combination compositions
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US10613081B2 (en) * 2016-11-27 2020-04-07 Alireza Palangi Quality control system and kit for automated ELISA devices
CN109385401A (zh) * 2017-08-10 2019-02-26 北京泰德制药股份有限公司 一种表达重组蛋白的cho细胞的培养方法
ES2936149T3 (es) * 2017-09-21 2023-03-14 Codiak Biosciences Inc Producción de vesículas extracelulares en suspensión unicelular utilizando medios de cultivo de células químicamente definidos
CA3198255A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
WO2019079520A2 (en) 2017-10-18 2019-04-25 Alpine Immune Sciences, Inc. ICOS VARIANT LIGAND IMMUNOMODULATORY IMMUNOMODULATORY PROTEINS, COMPOSITIONS AND METHODS THEREOF
JP7102734B2 (ja) * 2018-01-09 2022-07-20 東洋製罐グループホールディングス株式会社 細胞培養方法及び装置
US20190324000A1 (en) * 2018-04-20 2019-10-24 Janssen Biotech, Inc. Chromatography column qualification in manufacturing methods for producing anti-tnf antibody compositions
AU2019372675A1 (en) * 2018-11-02 2021-02-04 Beijing Vdjbio Co., Ltd. Modified CTLA4 and methods of use thereof
US11965900B2 (en) * 2018-11-09 2024-04-23 Wyatt Technology, Llc Indicating a status of an analytical instrument on a screen of the analytical instrument
EP3983781A4 (en) * 2019-06-14 2023-05-10 Agilent Technologies, Inc. METHODS AND KITS FOR IMPROVING THE FLUORESCENCE SIGNAL OF DMB-LABELED SIALIC ACIDS
US20220288095A1 (en) * 2019-07-26 2022-09-15 Lifescience As Sialic acid for use in the treatment of psoriasis
CN110554107B (zh) * 2019-08-14 2022-06-10 上海应用技术大学 一种高效液相色谱-质谱联用分析食用油中甘油三酯成分的方法
JP2023503442A (ja) 2019-11-21 2023-01-30 ブリストル－マイヤーズ スクイブ カンパニー 無標識ｎ－グリカン定量化方法
CN111398308B (zh) * 2020-03-27 2023-01-17 上海健康医学院 一种片剂、胶囊铝塑泡罩包装质量自动检测方法及系统
JP7415771B2 (ja) 2020-04-24 2024-01-17 株式会社島津製作所 分析支援装置、分析支援方法および分析支援プログラム
JP7415783B2 (ja) * 2020-05-12 2024-01-17 株式会社島津製作所 分析支援装置、分析支援方法および分析支援プログラム
WO2022036232A2 (en) * 2020-08-14 2022-02-17 Bristol-Myers Squibb Company Method of making protein
US20230313259A1 (en) * 2020-08-14 2023-10-05 Bristol-Myers Squibb Company Manufacturing process for protein
CN112198302B (zh) * 2020-10-25 2022-12-16 中铁二局第一工程有限公司 一种细集料含泥量快速检测方法及测量工具
JP2024503408A (ja) * 2021-01-20 2024-01-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 細胞培養におけるタンパク質力価の改善方法
CA3113278A1 (en) * 2021-03-25 2022-09-25 Lumex Instruments Canada (0890278 B.C. Ltd.) Device for electrophoretic analysis of multicomponent liquid samples
WO2022208550A1 (en) * 2021-03-31 2022-10-06 Dr. Reddy's Laboratories Limited Cell culture process for fusion protein composition
CN113241192B (zh) * 2021-05-18 2023-06-20 武汉大学中南医院 一种证据合成方法和计算机设备
WO2023053031A1 (en) * 2021-09-28 2023-04-06 Kashiv Biosciences, Llc An improved process of purification of fusion protein
WO2023053030A1 (en) * 2021-09-28 2023-04-06 Kashiv Biosciences, Llc An improved process for purification of protein
WO2023115027A2 (en) * 2021-12-16 2023-06-22 Bristol-Myers Squibb Company Detergent for viral inactivation
WO2023112992A1 (ja) * 2021-12-16 2023-06-22 レグセル株式会社 免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物
WO2023178329A1 (en) * 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
CN117044627B (zh) * 2023-10-11 2023-12-15 中国科学院昆明植物研究所 一种高山植物塔黄的组培快繁及离体保存方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460694A (en) * 1981-03-26 1984-07-17 University Of Miami Bovine glycoproteins and use in diagnosing infectious mononucleosis
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
DE122007000078I2 (de) 1991-06-27 2011-01-13 Bristol Myers Squibb Co CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
AU3144193A (en) * 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
AU7729194A (en) * 1993-09-15 1995-04-03 Alpha Therapeutic Corporation Alpha1-acid glycoprotein purification process and product
US5451660A (en) * 1993-12-13 1995-09-19 Genentech, Inc. Method for purifying polypeptides
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
AU2701895A (en) 1994-06-07 1996-01-05 Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
CN1268639C (zh) 1996-11-15 2006-08-09 基因技术股份有限公司 神经营养蛋白的纯化
DE69739673D1 (de) 1996-11-27 2009-12-31 Genentech Inc Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030124614A1 (en) 1997-08-29 2003-07-03 Brighams And Womens Hospital Inc. Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
WO1999028455A1 (de) 1997-12-03 1999-06-10 Roche Diagnostics Gmbh Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
CA2333747C (en) 1998-06-01 2008-02-19 Genentech, Inc. Separation of protein monomers by use of ion-exchange chromatography
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6521419B1 (en) 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6506598B1 (en) 1999-04-26 2003-01-14 Genentech, Inc. Cell culture process
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
CA2404155C (en) * 2000-03-27 2011-08-09 Genetics Institute, Llc. Methods for purifying highly anionic proteins
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
TWI314933B (en) 2000-05-26 2009-09-21 Bristol Myers Squibb Compan Soluble ctla4 mutant molecules and uses thereof
CN1438894A (zh) 2000-06-09 2003-08-27 布里斯托尔-迈尔斯斯奎布公司 通过阻断淋巴细胞信号和阻断lfa－1介导的粘附作用调节细胞介导的免疫应答的方法
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
AU2001272978A1 (en) 2000-06-23 2002-01-08 Maxygen, Inc. Novel co-stimulatory molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
WO2002002638A2 (en) * 2000-07-03 2002-01-10 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble ctla4 molecule
US6358265B1 (en) 2000-07-18 2002-03-19 Specialized Health Products, Inc. Single-step disposable safety lancet apparatus and methods
PL375139A1 (en) * 2001-01-26 2005-11-28 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
ATE390931T1 (de) 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
ATE363541T1 (de) * 2002-03-26 2007-06-15 Lek Tovarna Farmacevtskih Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen
JP2005521401A (ja) 2002-03-27 2005-07-21 イミュネックス・コーポレーション ポリペプチド産生を増加させる方法
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
CA2482042A1 (en) 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
US20060234226A1 (en) 2002-04-26 2006-10-19 Fahner Robert L Non-affinity purification of proteins
WO2004000810A1 (en) 2002-06-19 2003-12-31 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. A process for the production of substituted phenyl ethers
MXPA05000552A (es) * 2002-07-15 2005-04-28 Immunex Corp Metodos y medios para controlar la sialilacion de proteinas producidas por celulas de mamifero.
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
JP4496086B2 (ja) * 2002-12-23 2010-07-07 ブリストル−マイヤーズ スクイブ カンパニー タンパク質製造のための哺乳類細胞培養方法を用いる生成物品質の増大
PL377731A1 (pl) 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Sposoby hodowli komórek ssaczych do wytwarzania białka
ES2349779T5 (es) 2003-04-04 2013-11-26 Genentech, Inc. Formulaciones de anticuerpos y de proteínas a concentración elevada
US7118222B2 (en) * 2003-05-12 2006-10-10 Seiko Epson Corporation Optical device and protector
WO2005003175A2 (en) * 2003-06-13 2005-01-13 Biogen Idec Ma Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
KR20060132541A (ko) * 2003-08-04 2006-12-21 브리스톨-마이어스 스큅 컴퍼니 가용성 ｃｔｌａ4 분자를 사용한 심혈관 질환의 치료 방법
WO2005042569A1 (en) 2003-10-24 2005-05-12 Amgen, Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
EP1699821B1 (en) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI398520B (zh) 2005-12-20 2013-06-11 必治妥美雅史谷比公司 組合物及製造組合物之方法
CA2634547C (en) 2005-12-20 2016-10-11 Bristol-Myers Squibb Company Stable ctla4 formulation for subcutaneous administration
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
WO2008025747A1 (en) 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
UA99262C2 (uk) 2006-08-28 2012-08-10 Арес Трейдінг С.А. СПОСІБ ЗМЕНШЕННЯ КОНЦЕНТРАЦІЇ ВІЛЬНИХ Fc-ЧАСТИН В РІДИНІ, ЩО МІСТИТЬ Fc-ВМІСНИЙ БІЛОК

Also Published As

Publication number Publication date
CA2634760C (en) 2014-09-09
EA017765B1 (ru) 2013-03-29
PL1969007T4 (pl) 2014-04-30
MX336807B (es) 2016-02-02
IL229904A0 (en) 2014-01-30
CN106589132B (zh) 2022-03-29
EP1969007B1 (en) 2013-08-28
AU2010241289A1 (en) 2010-12-02
PE20080556A1 (es) 2008-06-13
EA200801571A1 (ru) 2010-02-26
CA2836123A1 (en) 2007-07-05
EP1969007A2 (en) 2008-09-17
ZA200805301B (en) 2012-11-28
CA2836123C (en) 2017-09-12
SI2253644T1 (sl) 2014-03-31
PT1969007E (pt) 2013-12-10
JP5096369B2 (ja) 2012-12-12
PT2253644E (pt) 2014-01-23
JP5097194B2 (ja) 2012-12-12
SI1969007T1 (sl) 2014-03-31
DK1969007T3 (da) 2013-11-25
HRP20130975T1 (hr) 2013-11-22
JP2009520503A (ja) 2009-05-28
IL192098A0 (en) 2008-12-29
AU2006330922B2 (en) 2012-07-26
NZ597215A (en) 2012-11-30
AU2006330922A1 (en) 2007-07-05
BRPI0622251A2 (pt) 2011-07-19
IL192098A (en) 2014-01-30
US10508144B2 (en) 2019-12-17
AU2010241289B2 (en) 2012-09-13
US20190062399A1 (en) 2019-02-28
EP2253644B1 (en) 2013-10-16
JP2010116402A (ja) 2010-05-27
BRPI0620178A2 (pt) 2010-06-29
US20190092835A1 (en) 2019-03-28
TWI398520B (zh) 2013-06-11
NO20082716L (no) 2008-09-19
US20210246188A1 (en) 2021-08-12
US10808021B2 (en) 2020-10-20
KR20080090428A (ko) 2008-10-08
ES2433092T3 (es) 2013-12-09
HK1121173A1 (en) 2009-04-17
CY1114887T1 (el) 2016-12-14
KR101398713B1 (ko) 2014-06-12
TWI423986B (zh) 2014-01-21
CA2634760A1 (en) 2007-07-05
BRPI0620178B1 (pt) 2022-08-23
WO2007076032A3 (en) 2008-04-03
TW201313742A (zh) 2013-04-01
PL1969007T3 (pl) 2014-01-31
KR101391457B1 (ko) 2014-05-19
TW200745334A (en) 2007-12-16
CN106589132A (zh) 2017-04-26
US20090252749A1 (en) 2009-10-08
KR20120010275A (ko) 2012-02-02
ES2439641T3 (es) 2014-01-24
EP2253644A1 (en) 2010-11-24
PL2253644T3 (pl) 2014-04-30
US10941189B2 (en) 2021-03-09
WO2007076032A2 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
DK2253644T3 (da) Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
FR22C1008I2 (fr) Composition immunogène
DK2087002T3 (da) Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
DK2460820T3 (da) PCV2-immunogene sammensætninger og fremgangsmåder til fremstilling af sådanne sammensætninger
DK2001611T3 (da) Fremgangsmåde og sammensætning til oprensning af jord
DK2135603T3 (da) Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
DK1852430T3 (da) Fremgangsmåde til fremstilling af proanthocyanidinoligomer
DK1856374T3 (da) Sammensætning og fremgangsmåde til fremstilling af et støttemiddel
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK2041071T3 (da) Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade
DK2203478T3 (da) Sammensætninger og fremgangsmåder til anvendelse af antistoffer mod sclerostin
DK3207941T3 (da) Fremgangsmåder og sammensætninger på basis af diphtheritoksin-interleukin-3-konjugater
DK1898829T3 (da) Fremgangsmåde til fremstilling af en tandprotesedel og således fremstillet tandprotesedel
DK1730259T3 (da) Fremgangsmåde til fremstilling af en sammensætning omfattende tørrede mikroorganismer
DK3308788T3 (da) Sammensætninger og fremgangsmåder til modulering af smn2-splejsning
ITMI20041252A1 (it) Composizioni perfluoroelastomeriche
DE602006020159D1 (de) Härtbare silikonzusammensetzung
DK2010501T3 (da) Imidazolbaserede forbindelser, sammensætninger omfattende disse og fremgangsmåder for deres anvendelse
NO20055686D0 (no) Sammensetning
DK3081215T3 (da) Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin
DK1891208T3 (da) Hidtil ukendte cellulære sammensætninger og fremgangsmåder til fremstilling deraf
DK1774566T3 (da) Sammensætninger til afgivelse af kviksölv og fremgangsmåde til fremstilling deraf
GB0508497D0 (en) Concrete composition
DK1612200T3 (da) Gødningssammensætning
DE502006006590D1 (de) Biozide zusammensetzungen